Primary Percutaneous Coronary Intervention in CAD Patients: A Comparison of Major Adverse Cardiovascular Events of Second- and Third-generation Drug-eluting Stents

Overview

Journal Front Pharmacol

Date 2022 Dec 5

PMID 36467026

Authors

Salma Bibi

Amjad Khan

Amer Hayat Khan

Muhammad Niaz Khan

Saima Mushtaq

Sheikh Abdur Rashid

Affiliations

Soon will be listed here.

Abstract

Biodegradable polymer (BP) drug-eluting stents (DES) have been introduced as a novel solution to the problems of durable polymer (DP) stents. In Pakistan, very few studies are available for the treatment intervention in post-primary percutaneous coronary intervention (PPCI) patients. Our study will compare the major adverse cardiovascular events (MACEs) and their predictors in patients with coronary artery disease (CAD) undergoing PPCI with second- or third-generation DES. An observational, retrospective, cohort study was carried out on CAD patients undergoing PPCI with either second- (DP-XIENCE Prime/XIENCE Xpedition) or third-generation (BP-BioMatrix NeoFlex/BioMatrix Alpha) DES. MACEs were assessed after 1 year of PPCI procedure in 341 patients and screened as per inclusion/exclusion criteria (167 in the second-generation group and 174 in the third-generation group). The number of male patients (86.2%) was more than female patients in our study population. MACEs were reported in 4.19% patients after 1 year duration, and the percentage of MACEs was more in the second-generation DES group (4.77%) than in the third-generation group (3.44%); however, statistical analysis has not found any significant difference ( = 0.534). The rate of myocardial infarction (1.19% vs. 0.57%) and stent thrombosis (1.8% vs. 1.15%) was more in the second-generation DES group. However, restenosis (1.19% vs. 1.15%) and cardiac death (0.59% vs. 0.57%) were almost same in both groups. A significant association was found between MACEs and diabetes mellitus ( = 0.025), hypertension ( = 0.035), smoking ( = 0.008), and a family history of CAD ( = 0.018). BP-BioMatrix and DP-XIENCE DES have comparable clinical outcomes. Findings of the current study will assist the policy makers and healthcare providers in the rationalization of scarce resources and evidence-based patient care. However, longer follow-up studies are required for convincing results.

References

Ki Y, Park K, Kang J, Kim C, Han J, Yang H . Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry. J Interv Cardiol. 2020; 2020:3872704. PMC: 7061140. DOI: 10.1155/2020/3872704. View

Kim Y, Her A, Jeong M, Kim B, Hong S, Ahn C . A comparison of the impact of current smoking on 2-year major clinical outcomes of first- and second-generation drug-eluting stents in acute myocardial infarction: Data from the Korea Acute Myocardial Infarction Registry. Medicine (Baltimore). 2019; 98(10):e14797. PMC: 6417640. DOI: 10.1097/MD.0000000000014797. View

Zhang Y, Iqbal J, Windecker S, Linke A, Antoni D, Sohn H . Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. Heart. 2014; 101(4):271-8. DOI: 10.1136/heartjnl-2014-306359. View

Miyoshi T, Matsuoka H, Kawakami H, Dai K, Sato T, Watanabe K . Assessment of Second- and Third-Generation Drug-Eluting Stents on Chronic Coronary Angioscopy　- Multicenter Study on Intra-Coronary AngioScopy After Stent (MICASA) Prospective Data Analysis. Circ J. 2018; 82(7):1830-1835. DOI: 10.1253/circj.CJ-17-1396. View

Smith B, Warner M, Warner N, Hanson A, Smith M, Rihal C . Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents. Anesth Analg. 2018; 128(4):621-628. DOI: 10.1213/ANE.0000000000003408. View

Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y . Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol. 2013; 62(3):181-190. DOI: 10.1016/j.jacc.2013.04.045. View

Separham A, Sohrabi B, Aslanabadi N, Ghaffari S . The twelve-month outcome of biolimus eluting stent with biodegradable polymer compared with an everolimus eluting stent with durable polymer. J Cardiovasc Thorac Res. 2013; 3(4):113-6. PMC: 3825338. DOI: 10.5681/jcvtr.2011.025. View

Wiemer M, Stoikovic S, Samol A, Dimitriadis Z, Ruiz-Nodar J, Birkemeyer R . Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up. Cardiovasc Diabetol. 2017; 16(1):23. PMC: 5301341. DOI: 10.1186/s12933-017-0500-3. View

Adnan Y, Noor L, Dar M, Ali U, Hafizullah M . Impact of stent length and diameter on short term clinical outcomes of drug eluting stents in patients with stable coronary artery disease. Pak J Med Sci. 2017; 33(4):959-962. PMC: 5648972. DOI: 10.12669/pjms.334.13068. View

10.

Tsai I, Wang C, Lu Y, Hung W, Wu C, Lu L . The burden of major adverse cardiac events in patients with coronary artery disease. BMC Cardiovasc Disord. 2017; 17(1):1. PMC: 5210314. DOI: 10.1186/s12872-016-0436-7. View

11.

Vlachojannis G, Smits P, Hofma S, Togni M, Vazquez N, Valdes M . Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus.... JACC Cardiovasc Interv. 2017; 10(12):1215-1221. DOI: 10.1016/j.jcin.2017.02.029. View

12.

Christiansen E, Jensen L, Thayssen P, Tilsted H, Krusell L, Hansen K . Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. Lancet. 2013; 381(9867):661-9. DOI: 10.1016/S0140-6736(12)61962-X. View

13.

Aghajani H, Nezami P, Shafiee A, Jalali A, Nezami A, Nozari Y . Predictors of Long-term Major Adverse Cardiac Events Following Percutaneous Coronary Intervention in the Elderly. Arch Iran Med. 2018; 21(8):344-348. View

14.

Lin M, Chen C, Lin H, Wu H . Impact of diabetes and hypertension on cardiovascular outcomes in patients with coronary artery disease receiving percutaneous coronary intervention. BMC Cardiovasc Disord. 2017; 17(1):12. PMC: 5217339. DOI: 10.1186/s12872-016-0454-5. View

15.

Giustino G, Baber U, Aquino M, Sartori S, Stone G, Leon M . Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization: From the WIN-DES Collaborative Patient-Level Pooled Analysis. JACC Cardiovasc Interv. 2016; 9(7):674-84. DOI: 10.1016/j.jcin.2015.12.013. View

16.

Parsa E, Saroukhani S, Majlessi F, Poorhosseini H, Lofti-Tokaldany M, Jalali A . Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study. Tex Heart Inst J. 2016; 43(2):126-30. PMC: 4845570. DOI: 10.14503/THIJ-14-4997. View

17.

Tsai M, Hsieh M, Chen C, Chang S, Wang C, Chen D . Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. Acta Cardiol Sin. 2020; 36(2):97-104. PMC: 7062815. DOI: 10.6515/ACS.202003_36(2).20190729A. View

18.

Park K, Lee J, Kang S, Ahn H, Yang H, Lee H . Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea.... J Am Coll Cardiol. 2013; 61(5):536-44. DOI: 10.1016/j.jacc.2012.11.015. View

19.

Lee D, de la Torre Hernandez J . The Newest Generation of Drug-eluting Stents and Beyond. Eur Cardiol. 2018; 13(1):54-59. PMC: 6159420. DOI: 10.15420/ecr.2018:8:2. View

20.

Maupas E, Lipiecki J, Levy R, Faurie B, Karsenty B, Moulichon M . Safety and efficacy outcomes of 3rd generation DES in an all-comer population of patients undergoing PCI: 12-month and 24-month results of the e-Biomatrix French registry. Catheter Cardiovasc Interv. 2017; 90(6):890-897. PMC: 5724651. DOI: 10.1002/ccd.27081. View